Success Story: NIW Approval Only Over 1 Month for a Dermatologist from Taiwan under Premium Processing
Client’s Testimonial:
"Overall, I greatly appreciate WeGreen’s professionalism, responsiveness, and support, and I would confidently recommend them to others pursuing immigration pathways such as EB-2 NIW."
On May 12th, 2026, we received another EB-2 NIW (National Interest Waiver) Approval for a Research Scholar in the Field of Dermatology (Approval Notice).
General Field: Dermatology
Position at the Time of Case Filing: Research Scholar
Country of Origin: Taiwan
State of Residence at the Time of Filing: California
Approval Notice Date: May 12th, 2026
Processing Time: 1 month, 6 days (Premium Processing Requested)
Case Summary:
An EB-2 NIW petition was recently approved in just over 1 month under premium processing without an RFE for a research scholar with an M.D. whose pioneering work in dermatology has advanced clinical care for vulnerable populations through groundbreaking contributions to skin aging and skin cancer research, drug safety for cutaneous adverse reactions, and pediatric skin disease management.
Research Leadership and National Impact
The client has established expertise in the field of dermatology, becoming a researcher in integrating epidemiological, observational, and clinical research with direct patient care to address skin aging, skin cancer, and systemic health risks in geriatric patients, as well as cutaneous adverse reactions to emerging therapeutics in vulnerable populations, including oncology and pediatric patients. This work directly supports U.S. national priorities in reducing the burden of skin cancer, strengthening dermatologic care for a rapidly aging population, and advancing health equity for underserved communities. The client's scholarly record reflects exceptional productivity and scientific impact:
- 7 peer-reviewed journal articles (6 of them first-authored)
- 132 citations
Expert Endorsements
To strengthen the NIW filing, our firm included 4 expert recommendation letters. One independent expert stated:
"Ultimately, [Client]'s work strengthens dermatologic precision medicine, fosters safer adoption of new interventions, and delivers tangible benefits to patients, clinicians, and the broader healthcare system across the United States."
NIW Approval and Outlook
This approval validates the client's sustained impact, exceptional scholarly record, and clear future benefit to the United States in advancing skin cancer prevention, improving outcomes for vulnerable populations, and strengthening the nation's capacity to address the dermatologic challenges of an aging society.
It has been an honor to support this accomplished physician-researcher throughout the petition process, and we extend our sincere best wishes for continued success in both professional and personal pursuits. We look forward to witnessing continued breakthroughs in skin frailty assessment, pediatric genodermatosis research, and evidence-based dermatologic care that will improve the quality of life for patients across the United States for years to come.

